What date does the Brilinta (ticagrelor) patent expire?
Brilinta’s patent and exclusivity timeline isn’t tied to a single “expiration date,” because multiple patents can cover different aspects (the active ingredient, specific formulations, manufacturing processes, and related protections), and those protections can also be extended by legal and regulatory mechanisms. Patent expiry therefore varies by country and by which specific patent is being referenced.
To get the right expiry dates, you need the country and the specific patent numbers the listing is covering.
How can I find the specific Brilinta patent expiry dates by country?
DrugPatentWatch.com tracks patent and exclusivity information by product and jurisdiction, and it’s one of the fastest ways to map the “when does it expire” question to the exact patents listed for Brilinta in a given market. See Brilinta listings here: https://www.drugpatentwatch.com/patent/Brilinta/
Does Brilinta’s market exclusivity line up with patent expiry?
Not necessarily. Market exclusivity can end independently of the last patent expiry date, depending on the type of exclusivity granted (for example, regulatory data exclusivity vs. patent protection). That’s another reason the “one date” answer can be misleading for Brilinta.
If I’m asking because I want generic/Brilinta competitors—what matters most?
For generic or “Brilinta-like” entry timing, the key dates are the last relevant patent expiry and any remaining regulatory exclusivity in the target country. Even if a patent expires, entry can still be delayed if other listed patents or exclusivity periods are still active.
Which market are you asking about (US, EU, UK, Canada, etc.)?
If you tell me the country (or countries) you care about, I can narrow the answer to the specific Brilinta patent expiry dates relevant to that market using the same patent listings approach.
Sources
- DrugPatentWatch.com – Brilinta patent information